Indication
Paragangliomas
1 clinical trial
2 products
1 drug
Clinical trial
Phase I/II Trial of Systemic Targeted Radioligand Therapy (TRT) With Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR Positive (SSTR+) Gastrointestinal (GI) Neuroendocrine Tumors (NET) and Pheochromocytoma/Paragangliomas Previously Treated With Systemic Radioligand TherapyStatus: Not yet recruiting, Estimated PCD: 2029-07-01
Drug
68Ga-DOTATATEProduct
[203Pb]VMT-alpha-NETProduct
[212Pb]VMT-alpha-NET